Gilteritinib (ASP2215) Liposomes

DLL-0021-1A-10ML

Gilteritinib (ASP2215) Liposomes

Gilteritinib (ASP2215) is a small-molecule inhibitor of FLT3/AXL with IC50 values of 0.29 nM and 0.73 nM for FLT3 and AXL, respectively. Gilteritinib (ASP2215) is a highly selective FLT3 inhibitor that demonstrates activity against both FLT3-ITD and FLT3-TKD mutation subtypes and selectively inhibits FLT3 at concentrations roughly 800-fold lower than those required to inhibit c-Kit (230 nM). This product is a pre-formulated liposomal version of Gilteritinib (ASP2215) which is supplied ready to use in vitro or in vivo. The liposomes are PEGylated for optimal in vivo performance; the lipid composition of the liposomes is the same as Doxil. For preclinical research use only.

4095 €

DLL-0021-1A-2ML

Gilteritinib (ASP2215) Liposomes

Gilteritinib (ASP2215) is a small-molecule inhibitor of FLT3/AXL with IC50 values of 0.29 nM and 0.73 nM for FLT3 and AXL, respectively. Gilteritinib (ASP2215) is a highly selective FLT3 inhibitor that demonstrates activity against both FLT3-ITD and FLT3-TKD mutation subtypes and selectively inhibits FLT3 at concentrations roughly 800-fold lower than those required to inhibit c-Kit (230 nM). This product is a pre-formulated liposomal version of Gilteritinib (ASP2215) which is supplied ready to use in vitro or in vivo. The liposomes are PEGylated for optimal in vivo performance; the lipid composition of the liposomes is the same as Doxil. For preclinical research use only.

995 €

MBS3840353-10mg

Gilteritinib (ASP2215)

491 €

DLL-0012-1D-5MG

Nexturastat A Liposomes

PEGylated liposomes containing Nexturastat A. Nexturastat A is a potent and selective HDAC6 inhibitor (IC50: 5 nM), with >190-fold selectivity over other HDACs. This product is a pre-formulated liposomal version of Nexturastat A which is supplied ready to use in vitro or in vivo. The liposomes are PEGylated for optimal in vivo performance. For preclinical research use only.

1195 €

DLL-0012-1E-1MG

Nexturastat A Liposomes

PEGylated liposomes containing Nexturastat A. Nexturastat A is a potent and selective HDAC6 inhibitor (IC50: 5 nM), with >190-fold selectivity over other HDACs. This product is a pre-formulated liposomal version of Nexturastat A which is supplied ready to use in vitro or in vivo. The liposomes are PEGylated for optimal in vivo performance. For preclinical research use only.

795 €

DLL-0012-1E-5MG

Nexturastat A Liposomes

PEGylated liposomes containing Nexturastat A. Nexturastat A is a potent and selective HDAC6 inhibitor (IC50: 5 nM), with >190-fold selectivity over other HDACs. This product is a pre-formulated liposomal version of Nexturastat A which is supplied ready to use in vitro or in vivo. The liposomes are PEGylated for optimal in vivo performance. For preclinical research use only.

1195 €